Mid-Cap NovaBridge Biosciences Stock Jumps Fueled By Positive Study Data In Eye Disease

Core Insights - NovaBridge Biosciences (NASDAQ:NBP) shares increased following positive Phase 2a study results for VIS-101, a treatment for retinal vascular diseases [1] Trial Data - The Phase 2a study showed that VIS-101 led to rapid and durable treatment responses in patients with wet age-related macular degeneration (wet AMD), which affects over 20 million people globally [2] - VIS-101 demonstrated mean Best Corrected Visual Acuity (BVCA) improvements of over 10 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters and median central subfield thickness (CST) reductions of 100-150 mm [2][3] - The study enrolled 38 patients in China and showed a favorable safety profile with no dose-limiting toxicity, positioning VIS-101 as a potential best-in-class treatment option [3] Future Plans - The company plans to initiate a dose-determining Phase 2b study in the second half of 2026, followed by a global Phase 3 program in 2027 [3] Technical Analysis - NovaBridge shares have decreased by 23.08% over the past 12 months, indicating a challenging year for the stock [5] - Currently, the stock is trading 14.2% above its 20-day simple moving average (SMA) and 4.4% above its 50-day SMA, suggesting short-term strength despite a longer-term downtrend [5] - The RSI is at 51.92, indicating neutral territory, while the MACD is at -0.0639, suggesting a bullish signal as it is above the signal line [6] Price Action - NovaBridge Biosciences shares were up 8.86% at $3.81 at the last check, with key resistance at $4.50 and key support at $3.50 [7]